Clinical Trials Browser

Recruiting × Carcinoma, Renal Cell × lenvatinib × Clear all

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT05327686 2026-04-08

SAMURAI

Phase 2 Recruiting

240 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

170 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

30 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04977453 2026-03-17

Keynote B59

Phase 1/2 Recruiting

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT07389629 2026-02-05

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Phase 2 Recruiting

25 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Recruiting

1,220 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

1,250 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05188118 2024-11-06

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

20 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Clinical Trials

MK-6482-043

SAMURAI

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Keynote B59

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

International Multicentric Study ARON-1

CARE1

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma